Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Jonsson Comprehensive Cancer Center
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04290897CT.gov Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Carcinoma In Situ
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anhydrous Enol-Oxaloacetate (this asset) | Jonsson Comprehensive Cancer Center | P2 | B · 57 |
| Exemestane | Alliance for Clinical Trials in Oncology | P4 | BBB |
| Letrozole | Alliance for Clinical Trials in Oncology | P4 | BBB |
| Tamoxifen | Alliance for Clinical Trials in Oncology | P4 | BB |
| Anastrozole | Alliance for Clinical Trials in Oncology | P4 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P3 | BB |
| Revaree Plus | Memorial Sloan Kettering Cancer Center | P4 | BB |
| Toremifene | Fred Hutchinson Cancer Center | P4 | BB |
| Dexasone | Ohio State University Comprehensive Cancer Center | P2/3 | B |
+20 more in the Breast Carcinoma In Situ cohort
Other indications for Anhydrous Enol-Oxaloacetate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P2 | B · 57 |
| Breast Cancer | — | P2 | B · 57 |
| Glioblastoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anhydrous Enol-Oxaloacetate in Breast Carcinoma In Situ. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anhydrous-enol-oxaloacetate-breast-carcinoma-in-situ
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →